Zimmer Biomet Holdings, Inc. Stock News

Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M.

WARSAW, Ind. , Aug. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2025.

WARSAW, Ind. , Aug. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the Annual Morgan Stanley Healthcare Conference on Monday, September 8, 2025, at 8:30 a.m.

Right now is not a good time in the healthcare sector. Various companies across the space are well below highs while the broader stock market chugs along at all-time highs.

Zimmer Biomet Holdings, Inc. (ZBH) Q2 2025 Earnings Call Transcript

Zimmer Biomet (ZBH -0.98%), an orthopedic medical technology company, reported its earnings on August 7, 2025. The company announced GAAP revenue of $2.077 billion, beating analyst estimates of $2.057 billion.

Zimmer Biomet Holdings raised its full-year adjusted profit forecast and beat second-quarter earnings expectations on Thursday, bolstered by accelerating demand for its hip and knee implants.

I reiterate my Buy rating on Zimmer Biomet Holdings, Inc., setting a fair value of $133 per ZBH share due to strong business acceleration opportunities. The Monogram Technologies acquisition could significantly enhance Zimmer's knee robotics, positioning it to better compete with Stryker through advanced autonomous technology. Paragon 28's integration is on track and expected to boost Zimmer's ...